Drug Discovery And Development Apac Companies - Top Drug Discovery Solution Companies In Apac

Pharma Tech Outlook: Pharma Tech Magazine

Genscript Probio: Biologics Backed by Pharmaceutical Proficiency

Top 10 Drug Discovery Solution Companies in APAC - 2021


While the COVID-19 pandemic definitely was the perfect storm, it was also one of the major reasons that pushed the pharma and life sciences field to mature rapidly, almost overnight. Even though the particular subset of the healthcare industry has been a little slow in terms of technology adoption, most players of this field now understand the crucial role technology plays in augmenting their current drug development capabilities, both in terms of speed and accuracy. The potential benefits of technology in healthcare are, therefore, vast, and revolutionary innovations like AI are clearing the way for a cost-effective, efficient and tailored approach to the production of medicinal products.

An important premise of AI is that it can support and analyze vast amounts of data. Critical aspects of the drug development pathway, such as biomarker discovery, outlier identification, and the creation of synthetic control arms, can all benefit from the utilization of AI. This is a far shift from the traditional drug-discovery stage of research, where potential disease targets are identified and testing occurs to understand whether a drug candidate can impact the identified target—a long and complex process that used to take 4-6 years to complete. AI has the potential to compress that timeline and optimize the process, leading to improved or more targeted molecules or compounds for development.

With such innovations boosting accuracy and efficiency, the pharma sector is standing at the cusp of the next digital transformation. In order to assist pharma organizations in shoring up their capabilities with robust solutions and effective services, we have compiled this issue of Pharma Tech Outlook. In this edition, we have listed the top 10 drug discovery solution providers to highlight the ones that can help you escalate your chances of success. Besides, the magazine comprises insights from subject matter experts, CIOs, and CXOs in the pharma sector. We hope this issue of Pharma Tech Outlook helps you build the partnership you and your organization need to foster an environment driven by robust and efficient technology.

We present to you Pharma Tech Outlook’s “Top 10 Drug Discovery Solution Providers in APAC – 2021.”

    Top Drug Discovery Solution Companies in APAC

  • A CDMO that offers pharmaceuticals a wholesome drug discovery and development service package for antibody discovery through to gene and cell therapy.From beginning to end, GenScript acts as ‘the pole star’ for pharma companies, guiding them in ensuring regulatory compliance and licensing of their biologic products for release in the consumer market.In addition, the CDMO has developed a quality assurance system to improve operations and assist pharma companies to ensure that every process is overseen with utmost scrutiny from start to finish of a drug discovery project


  • A biotechnology company based in China that realized the clinical development of blood glucose sensor glucokinase activator


  • Vyant Bio is at the vantage point in delivering a proprietary discovery engine driven by human biology and data science to rapidly move from novel biological target identification and therapeutic compounds identification to investigational new drug approvals at the regulatory level. The company's human-powered approach to drug discovery maximizes the likelihood of clinical success and helps translate therapeutics from discovery to the clinic. The company holds strong expertise in efficiently discovering novel neurology and oncology drugs. At its core, Vyant Bio's Human microOrgan discovery platform drives successful clinical outcomes through patient-based discovery. By integrating human-based microOrgan technology, state-of-the-art engineering, advanced data science, regulatory rigor, and a deep personal commitment to the field, the company identifies drugs from the most viable, safe, and effective drug candidates capable of transforming lives


  • Celltrion


    A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world’s first “antibody biosimilar” from a country with a relatively underdeveloped pharmaceutical sector. The company has pioneered numerous uncharted areas to stellar success, which it plans to follow up by continuing its growth as a global biopharmaceutical company with unique approaches to small molecule pharmaceuticals and new businesses such as the Ubiquitous-healthcare platform business

  • United BioPharma

    United BioPharma

    United BioPharma (UBP) is dedicated to the development and commercialization of proprietary monoclonal antibodies with significant impact to patients. The company has established a set of advanced antibody platform technologies in its state-of-the-art Research and Development and Manufacturing facilities based in Hsinchu, Taiwan

  • Ensol Biosciences

    Ensol Biosciences

    As a bio big data-based biopharmaceutical company that develops global innovative new drugs for diseases without therapeutic alternatives worldwide, such as degenerative disc, degenerative arthritis, TNBC, Alzheimer’s disease and type 1 diabetes, Ensol Biosciences applies bio big data-based BT/IT convergence technology from the aspects of drug efficacy, mechanism and toxicity, and side effects to develop outstanding drugs with high potential, and works on various discoveries and clinical trial phases systematically

  • Kinopharma


    KinoPharma is a clinical stage biopharma to research and develop small-molecule drugs based on new concept in areas of high medical need, such as antiviral drugs, and provide them to patients around the world who are waiting for them as quickly as possible

  • Mayne Pharma

    Mayne Pharma

    Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals. Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world

  • Sophion Bioscience

    Sophion Bioscience

    Sophion was founded in the year 2000 by a group of passionate electrophysiologists, all having the shared purpose of making patch clamping objective and independent of user skills to provide faster, more accurate and objective patch clamping results. The Sophion product range offers the most flexible automated patch clamp systems on the market today with QPatch and Qube384

  • WuXi Biologics

    WuXi Biologics

    WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients